Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.80 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.80 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249557 | 1.00 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824714 | 1.00 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8164843 | 1.00 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824723 | 1.00 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| Acrylonitrile SCHEMBL27703171 | 0.95 | PDE4A (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4823516 | 0.90 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4823519 | 0.90 | PDE4A (0.83) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL825369 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4826823 | 0.86 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816903 | 0.85 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | PDE4A 22/4885PDE4B 33/4885PDE4C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.